Roche ends small cell lung cancer trials as results show ‘reduced efficacy’
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.
Drugs
Health
Pharma
Drugs
Health
Pharma
Bird flu detected in a fourth person in the US, health agency CDC says
The national public health agency of the US has reported a fourth person who was infected in the country with the highly pathogenic.
Drugs
Health
Pharma
EMA approves Sanofi’s treatment for obstructive pulmonary disease
The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.
Drugs
Health
Pharma
Scotland’s medical university team cures Parkinson’s patient’s tremors
Scotland's researchers and doctors have performed a non-invasive operation on a patient with Parkinson’s disease using the country’s first ultrasound thalamotomy that allowed.
Drugs
Health
Pharma
FDA rejects Daiichi, Merck, antibody-drug conjugate application
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.
Drugs
Health
Pharma
Pfizer, BioNTech gets EMA marketing nod for variant Covid-19 vaccine
The European Medicines Agency has allowed marketing authorisation for the Covid-19 variant vaccine made by Pfizer and BioNTech SE for children aged six.
Drugs
Health
Pharma
Multivitamins play no role in improving your life span, finds study
HQ Team June 27, 2024:The ongoing debate about the perceived benefits or non-benefits of vitamin supplements has another study that emphasises their nil.
Drugs
Health
Pharma
USFDA issues new draft guidance for trials to expand race, ethnicity
In a bid to include an under-represented population, the US drug regulator has advised healthcare firms to improve racial, ethnic and other diversity.
Drugs
Health
Pharma
Novo’s end-stage hypertension trial drug fails, $817m impairment loss
Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.
